Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, Reduces oxidative stress, and increases fatty acid oxidation in moderately obese men

Diabetes

Volumn 57, Issue 2, 2008, Pages 332-339

  Risérus, Ulf ^a   Sprecher, Dennis ^b   Johnson, Tony ^b   Olson, Eric ^b   Hirschberg, Sandra ^b   Liu, Aixue ^b   Fang, Zeke ^b   Hegde, Priti ^b   Richards, Duncan ^c   Sarov Blat, Leli ^b   Strum, Jay C ^b   Basu, Samar ^d   Cheeseman, Jane ^a   Fielding, Barbara A ^a   Humphreys, Sandy M ^a   Danoff, Theodore ^b   Moore, Niall R ^e   Murgatroyd, Peter ^f   O'Rahilly, Stephen ^g   Sutton, Pauline ^a   Willson, Tim ^b   Hassall, David ^c   Frayn, Keith N ^a   Karpe, Fredrik ^a,h   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g GlaxoSmithKline ^*  (United Kingdom)

^h CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; APOLIPOPROTEIN B; CARBON DIOXIDE; CARNITINE PALMITOYL TRANSFERASE 1B; CARNITINE PALMITOYLTRANSFERASE I; GW 590735; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; THIAZOLE DERIVATIVE;

ABDOMINAL OBESITY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; EXHALATION; FAT CONTENT; FATTY ACID OXIDATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE URINE LEVEL; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MUSCLE BIOPSY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKELETAL MUSCLE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; APOLIPOPROTEINS B; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FATTY ACIDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBESITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLACEBOS; PPAR DELTA; THIAZOLES; TRIGLYCERIDES;

EID: 39649101196     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-1318     Document Type: Article

References (49)

1. Frayn KN: Adipose tissue as a buffer for daily lipid flux. Diabetologia 45:1201-1210, 2002
2. Perseghin G: Muscle lipid metabolism in the metabolic syndrome. Curr Opin Lipidol 16:416- 420, 2005
3. Yki-Jarvinen H: Fat in the liver and insulin resistance. Ann Med 37:347-356, 2005
4. Heilbronn L, Smith SR, Ravussin E: Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int J Obes Relat Metab Disord 28 (Suppl 4):S12-S21, 2004
5. Goodpaster BH, Wolf D: Skeletal muscle lipid accumulation in obesity, insulin resistance, and type 2 diabetes. Pediatr Diabetes 5:219-226, 2004
6. Petersen KF, Shulman GI: Etiology of insulin resistance. Am J Med 119:S10-S16, 2006
7. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
8. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J: Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 331:1188-1193, 1994
9. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
10. Hällsten K, Virtanen KA, Lönnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, Nuutila P: Rosiglitazone but not met-formin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51: 3479-3485, 2002
11. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA: Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719, 2001
12. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
13. The DREAM Trial Investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105, 2006
14. Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR: Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism 44:589-596, 1995
15. Nikkila EA, Huttunen JK, Ehnholm C: Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 26:179-186, 1977
16. Weisweiler P: Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia. Metabolism 38:271-274, 1989
17. de Man FH, de Beer F, van der Laarse A, Jansen H, Leuven JA, Souverijn JH, Vroom TF, Schoormans SC, Fruchart JC, Havekes LM, Smelt AH: The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis 153:363-371, 2000
18. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, Lahdenpera S, Taskinen MR: Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus: relations to lipolytic enzymes and to the cholesteryl ester transfer protein activity. Atherosclerosis 102:79-89, 1993
19. Simo IE, Yakichuk JA, Ooi TC: Effect of gemfibrozil and lovastatin on postprandial clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis 100:55-64, 1993
20. Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR: Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients. Artery 12:363-381, 1985
21. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J: Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: a potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95:705-712, 1995
22. Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, et al.: Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J Lipid Res 36:2541-2551, 1995
23. Lambert DA, Catapano AL, Smith LC, Sparrow JT, Gotto AM Jr: Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Atherosclerosis 127:205-212, 1996
24. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741-750, 1995
25. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE: The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17:2477-2493, 2003
26. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J: Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924-15929, 2003
27. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159-170, 2003
28. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM: Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294, 2004
29. Oliver WR, Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311, 2001
30. Terada S, Wicke S, Holloszy JO, Han DH: PPARdelta activator GW-501516 has no acute effect on glucose transport in skeletal muscle. Am J Physiol Endocrinol Metab 290:E607-E611, 2006
31. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM: PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad SciUSA 103:3444-3449, 2006
32. Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM,
33. Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG: Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol 27:359-365, 2007
34. Sierra ML, Beneton V, Boullay AB, Boyer T, Brewster AG, Donche F, Forest MC, Fouchet MH, Gellibert FJ, Grillot DA, Lambert MH, Laroze A, Le Grumelec C, Linget JM, Montana VG, Nguyen VL, Nicodeme E, Patel V, Penfornis A, Pineau O, Pohin D, Potvain F, Poulain G, Ruault CB, Saunders M, Toum J, Xu HE, Xu RX, Pianetti PM: Substituted 2-[(4-aminomethyl- )phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem 50:685-695, 2007
35. Marks SJ, Moore NR, Ryley NG, Clark ML, Pointon JJ, Strauss BJ, Hockaday TD: Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. Int J Obes 21:274-279, 1997
36. Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN: Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684-2690, 2002
37. Musiek ES, Yin H, Milne GL, Morrow JD: Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids 40:987-994, 2005
38. Basu S: Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 38:105-122, 2004
39. Basu S: Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 58:319-325, 1998
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
41. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
42. Vega GL, Cater NB, Hadizadeh DR 3rd, Meguro S, Grundy SM: Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther 74:236-244, 2003
43. Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, et al.: Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 74:2164-2177, 1984
44. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F: Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46:526-534, 2005
45. Sanyal AJ: Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2:46-53, 2005
46. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003
47. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
48. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95, 2005
49. Adiels M, Taskinen MR, Packard C, Caslake MJ, Soro-Paavonen A, Westerbacka J, Vehkavaara S, Hakkinen A, Olofsson SO, Yki-Jarvinen H, Boren J: Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49:755-765, 2006